Biotech stocks are ready to break out. They just need one more thing
Biotech stocks tend to outperform in the months leading up to an interest rate cut. But other factors are driving performance too.
Source: cnbc.com
Phathom Pharmaceutical News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Phathom Pharmaceutical. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Phathom Pharmaceutical Today - Breaking & Trending Today
With 47% ownership, Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) has piqued the interest of institutional investors
Key Insights Given the large stake in the stock by institutions, Phathom Pharmaceuticals' stock price might be...
Source: yahoo.com
FDA Accepts NDA for Vonoprazan (Voquenza) in Non-Erosive GERD
The NDA submission was supported by positive data from the phase 3 PHALCON-NERD-301 study and has been assigned a standard 10-month review with a PDUFA target action date of July 19, 2024.
Source: hcplive.com
Gastroenterology Month in Review: November 2023
November’s Gastroenterology Month in Review features an FDA approval, the discontinuation of a phase 3 clinical program, and news about Clostridioides difficile testing and risk factors.
Source: hcplive.com
FDA approves VOQUENZA ® to treat Erosive Esophagitis
VOQUENZA® provides quicker healing than Lansoprazole, according to an FDA-approved Phase 3 study
Source: hcplive.com